Etanercept at different dosages in the treatment of generalized pustular psoriasis: A case series

Dermatology

Volumn 216, Issue 4, 2008, Pages 355-360

  Esposito, M ^a   Mazzotta, A ^a   Casciello, C ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Biologics; Etanercept; Pustular psoriasis; Tumor necrosis factor

Indexed keywords

ANTIPSORIASIS AGENT; C REACTIVE PROTEIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; PREDNISOLONE; STEROID;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LONG TERM CARE; MALE; PRIORITY JOURNAL; PUSTULAR PSORIASIS; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43049122794     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117706     Document Type: Article

References (21)

1. Christophers E, Mrowietz U: Psoriasis; in Freedberg IM, Eisen AZ, Wolff K, Frank Austen K, Goldsmith LA, Katz SI (eds): Fitzpatrick's Dermatology in General Medicine, ed 6. New York, McGraw Hill, 2003, pp 407-427.
2. Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, Ikeda S, Ogawa H, Kawada A, Tezuka T, Igarashi A, Harada S: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003;295:S43-S54.
3. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632.
4. Leonardi CL, Powers JL, Matheson RT, Goffe GS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022.
5. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-1312.
6. Alexis AF, Strober BE: Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 2005;9:296-302.
7. Carrera C, Mascarò JM Jr, Moreno-Romero JA, Iranzo P, Palou J, Zamora E, Herrero C: Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept. Dermatology 2007;214:77-81.
8. Fredriksson T, Pettersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-244
9. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK: Biology of tumor necrosis factor-α - implications for psoriasis. Exp Dermatol 2004;13:193-222.
10. Costanzo A, Mazzotta A, Papoutsaki M, Nisticò S, Chimenti S: Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005;152:187-189.
11. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S: Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006;155:156-159.
12. Lisby S, Gniadecki R: Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol 2004;84:247-248.
13. Newland MR, Weinstein A, Kerdel FA: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-452.
14. Trent JT, Kerdel FA: Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004;8:224-228.
15. Weisenseel P, Prinz JC: Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 2006;78:197-199.
16. Kazinski K, Joyce KM, Hodson D: The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau. J Drugs Dermatol 2005;4:360-364.
17. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO: Generalized pustular psoriasis induced by cyclosporin A withdrawal responding to the tumor necrosis factor alpha inhibitor etanercept. Dermatology 2002;205:213-216.
18. Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS: Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006;213:350-352.
19. Heymann WR: Tumor necrosis factor inhibitor-induced pustular psoriasis. J Am Acad Dermatol 2007;56:327-329.
20. Goiriz R, Dauden E, Perez-Gals S, Guhl G, Garcia-Diez A: Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers. Clin Exp Dermatol 2007;32:176-179.
21. De Gannes GC, Goreishi M, Pope J, Russel A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-231.